Developmental Research Program

发展研究计划的目的是促进对创新思想的探索 通过资助试点项目进行肺癌的转化性研究。每年都有新的试点项目 申请由发展研究委员会征集，该委员会由邦恩博士担任主席。当前 委员会成员包括德拉布金博士、希斯利博士、富兰克林博士、赫希博士、巴伦博士和基思博士。一项请求 申请公告分发给科罗拉多大学所有联盟机构的教职员工 综合癌症中心(UCDHSC，CU-Boulder，科罗拉多州立大学，国立犹太医学 和研究中心，以及儿童医院)。平均每年收到11份申请。 委员会根据其新颖性、影响肺癌负担的可能性对每一项申请进行评分 通过翻译研究，其科学价值，以及调查人员的资格。它的用途 孢子资源和包括与现有孢子项目的合作也被纳入 对价。一般情况下，每年为两项申请提供50000美元的资助。一半的人 支持来自孢子基金，一半来自机构基金。在某些情况下，我们有 为有价值的项目提供部分资金，这些项目可以在更有限的支持下启动。在.期间 在最近的资金周期中，我们总共支持了12个试点项目。这些项目及其成果是 在下面的报告中进行了总结。我们的发展研究项目取得了成功 最近的一些试点项目进展为完全孢子项目。在这场竞争性的更新中， 项目3最初是一个试点项目。此外，希斯利博士和迈耶博士的试点项目的进展 所罗门博士、汉森和邓肯已被纳入项目2、3和4的目标， 分别进行了分析。Nemenoff博士、Heasley博士和Malkinson博士进行的试验项目导致了目前的NCI R01； 苏博士的试点项目导致了NIH R21；埃斯皮诺萨博士和希曼博士的试点项目是 整合到他们的NCI R01中。富兰克林博士和瓦雷拉博士的研究成果-- 加西亚在2005年被用于续签NCI EDRN赠款。同样，肺癌的遗传流行病学 GELCC和肺癌生物标志物和化学预防联盟(LCBCC)研究 也是孢子试点项目的成果。其他几项重要的肺癌赠款也得到了资助。 并在本报告中进行了描述。

The purpose of the Developmental Research Program is to promote the exploration of innovative ideas in translational research in lung cancer through the funding of pilot projects. Each year new pilot project applications are sought by the Developmental Research Committee, which is chaired by Dr. Bunn. Current committee members include Drs. Drabkin, Heasley, Franklin, Hirsch, Baron, and Keith. A request for application announcement is distributed to faculty at all consortium institutions of the University of Colorado Comprehensive Cancer Center (UCDHSC, CU-Boulder, Colorado State University, National Jewish Medical and Research Center, and The Children's Hospital). On average, 11 applications are received each year. The committee scores each application on its novelty, its likelihood of impacting the lung cancer burden through translational research, on its scientific merit, and on the qualifications of the investigators. The use of SPORE resources and the inclusion of collaborations with existing SPORE projects is also taken into consideration. Generally two applications are funded each year at a level of $50,000 each. Half of the support comes from SPORE funds and half comes from institutional funds. In some instances we have provided partial funding for worthy projects that could get started with more limited support. During the recent funding cycle we supported a total of 12 pilot projects. These projects and their outcomes are summarized in the following report. The success of our Developmental Research Program is demonstrated by the progression of a number of recent pilot projects into full SPORE projects. In this competitive renewal, Project 3 originated as a pilot project. As well, progress on the pilot projects of Dr. Heasley, of Dr. Meyer and of Drs. Solomon, Hansen and Duncan have been incorporated into the aims of Projects 2, 3 and 4, respectively. Pilot projects held by Drs. Nemenoff, Heasley, and Malkinson have led to current NCI R01s; the pilot project of Dr. Su has led to an NIH R21; and the pilot projects of Drs. Espinosa and Schiemann are incorporated into their NCI R01s. The research results from projects held by Drs. Franklin and Varella- Garcia were used to renew the NCI EDRN grant in 2005. As well, the Genetic Epidemiology Lung Cancer Consortium (GELCC) and the Lung Cancer Biomarkers & Chemoprevention Consortium (LCBCC) studies were also outcomes of SPORE pilot projects. Several other important lung cancer grants have been funded by other institutes and are described in this report.